DETAILED DESCRIPTION OF THE INVENTION The compounds of Formula I are useful as beta-adrenergic blockers in therapeutic treatment of antianginal, antiarrhythmic and antihypertensive conditions or are intermediates useful for the preparation thereof (see, for example, U.
S.
Pat.
No.
3,351,584).
The term "alkyl" or "alk" as used herein alone or as a part of another group, denotes such optionally substituted, but preferably unsubstituted, straight and branched chain saturated hydrocarbon groups, preferably having 1 to 10 carbons in the normal chain.
Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, t-butyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethyl, pentyl, octyl, 2,2,4-trimethyl pentyl, nonyl, decyl and the like.
The alkyl groups may be substituted by appropriate substituents, that is, substituents providing compounds suitable for use in the present invention.
Exemplary substituents of the alkyl group include one or more, preferably three or fewer, chloro groups, bromo groups, or iodo groups.
The terms "lower alk" or "lower alkyl" as used herein, denote such optionally substituted, but preferably unsubstituted, groups as described above for alkyl having 1 to 4 carbon atoms in the normal chain.
The term "lower alkoxy" denotes a lower alkyl group as described above bonded through an oxygen linkage (--O--).
The terms "monoalkylamino" or "dialkylamino" denote an amino group substituted by one or two alkyl groups as described above, respectively.
The term aryl used herein denotes homocyclic aromatic groups, preferably containing 1 or 2 rings and 6 to 12 ring carbons.
Exemplary aryl groups include phenyl, biphenyl, and naphthyl.
The terms "substituted aryl" and "substituted benzyloxy" denote groups wherein the aromatic ring or rings are substituted.
Exemplary substituents include one or more, preferably three or fewer, nitro groups, alkyl groups as described above or groups described above as substituents for the alkyl group.
The process of the present invention has the advantage of producing an enantiospecific result
|
Molecular Biology 
